Where’s the biosimilar revolution we were promised?

For years, the rise of biosimilars — nearly identical versions of biologic drugs — was expected to have a sweeping effect on the cost of medicine in the U.S., just as generics did for the pills of yesteryear. That didn’t happen, and the explanation weaves through legal pugilism, regulatory problems, and some industry profiteering.

In STAT’s latest report, Ed Silverman dives into the issue of biosimilars, explaining the history of the field, the barriers to its success, and the potential for off-brand biologics to finally fulfill those lofty projections from the past.

It adds up to more than 40 pages, with vital details to help people in industry, academia, and politics understand the complex issue. And you can buy it right here.